Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Nature. 2018 Sep 26;561(7724):479–484. doi: 10.1038/s41586-018-0531-2

Extended Data Figure 1. Study participant selection and demographics.

Extended Data Figure 1.

a, Flow diagram indicating the selection of study participants. b, Table showing individual participant demographics and baseline clinical characteristics. * EVG – elvitegravir, cobi - cobicistat, TDF - tenofovir disoproxil fumarate, FTC - emtricitabine, RPV - rilpivirine, EFV - efavirenz, TAF - tenofovir alafenamide fumarate, D, RTV – ritonavir, ABC – abacavir, 3TC - lamivudine, DTG – dolutegravir. ** NNRTI-based regimens were switched four weeks before ART interruption due to longer half-lives of NNRTIs. *** Pre-screening of bulk outgrowth virus obtained from PBMC culture by TZM-bl assay. # All participants harbored clade B viruses. Viral load < 20 D: Plasma HIV-1 RNA detected but not quantifiable by clinical assay. Dx, diagnosis; Scr, screening; Wk −2, week −2; d0, day 0. Grey shaded rows indicate participants who were found to have detectable viremia (HIV-1 VL > 20 copies/ml) at week −2 or day 0. These participants were not included in the efficacy analyses given lack of viral suppression at baseline.